July 12, 2014 11:49 AM ET

Biotechnology

Company Overview of Laboratoire Français du Fractionnement et des Biotechnologies Société Anonyme

Company Overview

Laboratoire Français du Fractionnement et des Biotechnologies Société Anonyme, a biopharmaceutical company, develops, manufactures, and markets medicinal products for the treatment of serious and rare diseases in the therapeutic areas of immunology, haemostasis, and intensive care worldwide. The company offers immunoglobulins, such as TEGELINE, which is used for multifocal motor neuropathy and chronic inflammatory demyelinating polyradiculoneuropathy; CLAIRYG, a ready-to-use liquid polyvalent human immunoglobulin; and hepatitis B immunoglobulin for hepatitis B immunoprophylaxis treatment. It also provides FACTANE, WILFACTIN/WILSTART, and BETAFACT for haemostasis disorders and pneumology. The...

3, avenue des Tropiques

ZA Courtaboeuf

Les Ulis,  91940

France

1,950 Employees

Phone:

33 1 69 82 70 10

Fax:

33 1 69 07 19 03

Key Executives for Laboratoire Français du Fractionnement et des Biotechnologies Société Anonyme

Chairman
Age: 54
Head of Financial Affairs & Strategy
Chief Executive Officer of LFB Hemoderivados e Biotecnologia - Brazil
Chief Scientific Officer and Head of Scientific & Medical Operations
Age: 61
Managing Director of Europlasma AT GmbH
Compensation as of Fiscal Year 2014.

Laboratoire Français du Fractionnement et des Biotechnologies Société Anonyme Key Developments

LFB SA Begins First Patient Treatment with New Coagulation Factor VIIa (Recombinant) in Global Phase 3 Clinical Trial in Hemophilia A and B with Inhibitors

LFB SA, through its U.S. subsidiary, announced that the first patient has begun treatment with LR769 in a Phase 3 clinical trial of this novel recombinant form of human Factor VIIa in patients with congenital hemophilia A or B with inhibitors. This Phase 3 clinical trial is a global open-label, multicenter study designed to evaluate the efficacy, safety and pharmacokinetics of LR769 in adolescent and adult hemophilia A and B patients with inhibitors. The study will evaluate two dosing regimens for the treatment of bleeding episodes and should be completed in 2015. The start of patient treatment is an important milestone in the development of LR769 for hemophilia A and B patients with inhibitors to Factor VIII or IX. Based on promising data from earlier studies, the company believes that LR769 has the potential to be a significant advance for people with hemophilia, and it will fully explore its potential as the first new therapeutic option in more than 15 years. Additional Phase 3 studies will assess the efficacy of LR769 for the treatment of bleeding episodes in pediatric hemophilia patients with inhibitors and will evaluate the prevention of bleeding complications in patients undergoing surgery. These studies are expected to start in early 2015.

LFB SA Initiates Global Phase 3 Clinical Trial of New Coagulation Factor VIIa (Recombinant) in Patients with Hemophilia A and B

LFB SA announced initiation of the global Phase 3 program for LR769, a novel recombinant form of human Factor VIIa, in patients with congenital hemophilia A or B with inhibitors. LR769 was developed using rPRO(TM) technology and is being developed for treatment and prevention of bleeding episodes in hemophilia A and B patients with inhibitors to Factor VIII or IX. The initial Phase 3 clinical trial is an open-label, multicenter study designed to evaluate the efficacy, safety and pharmacokinetics of LR769 in adolescent and adult hemophilia A and B patients with inhibitors. The study will evaluate two dosing regimens for the treatment of bleeding episodes. Initial results, expected in the second half of 2013, will provide the basis for subsequent studies. The second study will assess the efficacy of LR769 for the treatment of bleeding episodes in pediatric hemophilia patients with inhibitors. The third study will evaluate the prevention of bleeding complications in patients undergoing surgery. Both are expected to start early 2015.

Similar Private Companies By Industry

Company Name Region
SeleXel Europe
MAT Biopharma SAS Europe
Eco Process Energie Environnement Europe
S.A. Nanomakers Europe
Millegen S.A. Europe

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Laboratoire Français du Fractionnement et des Biotechnologies Société Anonyme, please visit www.lfb.fr. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.